NYSE:JNJPharmaceuticals
Johnson And Johnson PFA Launch In Europe Puts MedTech In Focus
Johnson & Johnson (NYSE:JNJ) has launched its VARIPULSE Pro pulsed field ablation system in Europe for cardiac arrhythmia procedures.
The European rollout introduces a faster and more efficient PFA workflow that is paired with an established safety profile.
The launch is supported by pivotal clinical data presented at a major European electrophysiology conference.
For investors tracking NYSE:JNJ primarily through its pharmaceutical and immunology headlines, VARIPULSE Pro puts the MedTech...